Chen-en Tsai

Biography

Dr. Tsai joined TWi Biotechnology in May 2015 as Vice President of clinical and medical affairs. He oversees clinical development, medical affairs activities and drug safety. His career path has spanned clinical services, basic medical research, hospital management, regulatory science, the pharmaceutical industry and HTA (health technology assessment). Prior to joining TWi, Dr. Tsai acted as Vice President of Clinical Development at TaiGen Biotechnology. In that role, he supervised the design, initiation and execution of phase 1 to phase 4 studies, led all medical affairs activities, and was the clinical and medical expert for the company’s initial public offering in Taiwan. Dr. Tsai also previously worked as a Senior Principal Researcher at the Division of Clinical Sciences (reviewing new drugs and medical devices) and HTA, Center for Drug Evaluation, Taiwan, for five years. His comprehensive experience with designing, managing and reviewing clinical trials was accumulated through working as a trial principal investigator at a medical center, a Medical Advisor at Bristol-Myers Squibb (Taiwan and Hong Kong) and a Senior Principal Researcher at the CDE. He also has well-rounded clinical training and 12 years of clinical practice in medical centers in Taiwan. Dr. Tsai obtained his medical degree from National Taiwan University and Ph.D. in molecular genetics from Cambridge University, UK.

Research Interest

Dermatology